Evaluating an Acquisition from the Target Firm's Viewpoint - Bobinac, Ziga
32,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
  • Broschiertes Buch

Evaluating acquisitions is a delicate matter because it is difficult to assume what would have happened in the absence of a deal. This book tries to assess Novartis' acquisition in terms of the impact on the Slovenian generic pharmaceutical company Lek. Facing several problems with how to measure the effects of M&A on the acquired firm, success can be assessed from two main aspects: a.) The degree to which previously set goals have been reached; and b.) The performance of the acquired firm in comparison to its peers in key areas of the sector. With insights from 4 C-level members of Lek and…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Evaluating acquisitions is a delicate matter because it is difficult to assume what would have happened in the absence of a deal. This book tries to assess Novartis' acquisition in terms of the impact on the Slovenian generic pharmaceutical company Lek. Facing several problems with how to measure the effects of M&A on the acquired firm, success can be assessed from two main aspects: a.) The degree to which previously set goals have been reached; and b.) The performance of the acquired firm in comparison to its peers in key areas of the sector. With insights from 4 C-level members of Lek and Krka, this book offers a unique understanding of reasons for taking very different paths of two leading Slovenian companies in the last 20 years.
Autorenporträt
Ziga Bobinac is Master of Science in International Business in Copenhagen Business School. He has started his professional career in Business Consulting and has moved to Mobile Gaming in 2014. Ziga has extensive international business experience, as he worked in Slovenia, France, Denmark and Norway.